The Biggest Revenue Opportunity in Your Practice Isn't More Patients; It's the Revenue You're Already Earning, says ModuleMD Report

ModuleMD’s 2026 thought-leadership report argues Allergy & Immunology practices can unlock revenue by reducing revenue leakage in the revenue cycle (e.g., nearly 60% of claims still require manual staff intervention, and a 3-point Net Collection Rate improvement could drive $156,000+ in annual opportunity per provider). It highlights that 43.6% of biologic prescriptions face delay/denial before treatment starts and links KPI optimization (A/R days, net collection rate, denial reduction, point-of-service collections, automation) to improved cash flow and profitability. The article is informational with no direct financial results disclosed, implying limited near-term market impact.

Analysis

This is more a vendor credibility check than a market catalyst. The economic read-through is that specialty practices are under margin pressure and will keep buying tools that reduce labor per claim, but that demand is usually incremental, budget-constrained, and slow to translate into public-company revenue unless the vendor can show bookings, retention, and workflow lock-in. In other words: the theme is real, the press release is not proof.

Second-order, the bigger beneficiary is not necessarily the software seller but the practices that can amortize admin overhead across larger platforms. If auth friction and manual claim touches keep rising, independent allergy groups are more likely to consolidate into PE-backed MSOs or outsource RCM, which is mildly negative for standalone clinics and positive for integrated workflow providers. Public-market proxies like MDRX or EXLS are cleaner expressions than a thinly traded microcap because the upside depends on measurable conversion, not narrative.

Time horizon matters: over the next few days this should trade like a non-event unless there is a real contract or filing. Over 1-3 months, watch for evidence that the pricing conversation turns into signed deployments or improved retention; absent that, any bounce is likely faded. Over 6-18 months, the durable winner is whoever can embed auth, billing, and inventory into one workflow and prove lower churn, but the risk is that payer tightening can also suppress procedure volumes and offset software gains.

Key Decisions for Investors

• No immediate position in HRDI; treat this as a low-conviction marketing update, not a fundamental inflection.
• If HRDI gaps up >5-8% on the release without disclosed bookings, customer wins, or ARR data, consider fading the move with a tight stop above the post-announcement high; thesis decay window is 3-10 trading days.
• Add a 1-2 quarter watch item on HRDI for any evidence of customer count growth, net revenue retention, or margin improvement; those are the only data points that would justify re-rating the story.
• For a cleaner public-market proxy, prefer monitoring MDRX and EXLS for confirmation that specialty-practice workflow and RCM automation are converting into actual spend; only act if management commentary shows measurable pipeline or margin leverage.
• Falsifier for any bearish fade: a disclosed multi-site deployment, material contract value, or clear ARR/bookings acceleration in the next quarter; if that happens, cover and reassess.